Reasons to Retain Fresenius Medical Stock in Your Portfolio for the Time Being
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 23 2025
0mins
Source: NASDAQ.COM
Company Overview: Fresenius Medical Care AG & Co. (FMS) is a leading provider of dialysis products and services, with a market cap of $15.11 billion and a strong global presence, having expanded through strategic acquisitions and partnerships.
Financial Performance: FMS shares have increased by 13.3% year-to-date, outperforming the industry, with earnings expected to grow by 12.6% over the next five years, despite facing challenges from rising costs and labor market issues.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVST
Wall Street analysts forecast NVST stock price to fall
13 Analyst Rating
5 Buy
7 Hold
1 Sell
Moderate Buy
Current: 27.130
Low
18.00
Averages
22.22
High
27.00
Current: 27.130
Low
18.00
Averages
22.22
High
27.00
About NVST
Envista Holdings Corporation is a global dental products company. The Company's diversified portfolio of solutions covers a range of dentists' clinical needs for preventing, diagnosing, and treating dental conditions as well as improving the aesthetics of the human smile. It has more than 30 dental brands, including Nobel Biocare, Ormco, DEXIS and Kerr. Its segments include Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment primarily develops, manufactures and markets dental implant systems, including regenerative solutions, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. The Equipment & Consumables segment primarily develops, manufactures, and markets dental equipment and supplies used in dental offices, including digital imaging systems, software, and other visualization/magnification systems; and endodontic systems and related products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Envista to Report Q2 2026 Financial Results on August 5
- Earnings Release Schedule: Envista Holdings Corporation will report its Q2 2026 financial results on August 5, 2026, and will hold a conference call at 2:00 PM PT on the same day, lasting approximately one hour, reflecting the company's commitment to transparency and investor communication.
- Webcast and Replay: The conference call and accompanying slides will be webcast on the 'Investors' section of Envista's website, with a replay available for one year post-presentation, ensuring investors can access critical information at their convenience.
- Dial-in Participation: Investors can join the call by dialing 1-800-836-8184 within the U.S. or +1 646-357-8785 internationally a few minutes before 2:00 PM PT, referencing Conference ID #73468, demonstrating the company's focus on facilitating investor engagement.
- Company Background: Envista is a global leader in the dental industry, uniting over 30 trusted brands dedicated to improving patient lives through innovative technologies and services, showcasing its significant impact on modern dentistry.
See More
Envista to Report Q2 2026 Financial Results on August 5
- Earnings Release Schedule: Envista Holdings Corporation will report its Q2 2026 financial results on August 5, 2026, and will hold a conference call at 2:00 PM PT on the same day, lasting approximately one hour, reflecting the company's commitment to transparency and investor communication.
- Webcast and Replay: The conference call and accompanying slides will be webcast on the 'Investors' section of Envista's website, with a replay available for one year post-presentation, ensuring investors have access to critical information at their convenience.
- Dial-in Participation: Investors can participate by dialing 1-800-836-8184 within the U.S. or +1 646-357-8785 internationally a few minutes before the call, referencing Conference ID #73468, demonstrating the company's openness to global investor engagement.
- Company Background: Envista is a global leader in the dental industry, uniting over 30 trusted brands focused on improving patient lives through innovative technologies and services, showcasing its deep expertise and market influence in the dental sector.
See More
Henry Schein Appoints New Board Chairman
- New Board Chairman: Henry Schein announced that William K. 'Dan' Daniel will become the Independent Chairman of the Board effective May 21, 2026, succeeding Stanley M. Bergman, who served 44 years and is now Chairman Emeritus, recognizing his extraordinary contributions to the company.
- Rich Leadership Experience: Daniel joined the Henry Schein Board in May 2025 and brings decades of board and global executive leadership experience in healthcare and industrial sectors, having served 14 years as Executive Vice President at Danaher Corporation, overseeing multiple business segments including the dental portfolio.
- Strategic Continuity and Growth: Daniel expressed his commitment to building upon the foundation laid by Bergman, emphasizing the latter's strategic leadership and dedication to Henry Schein's mission, which has shaped the company into a leading industry provider, and he looks forward to supporting this legacy.
- Growth Outlook: CEO Fred Lowery expressed gratitude for Bergman's contributions and highlighted that Daniel's deep understanding of the business and distinguished track record will be instrumental in executing the company's long-term strategy, enhancing the quality and accessibility of healthcare services.
See More
Envista Reports Strong Q1 Sales Growth Amid Challenges
- Strong Sales Performance: Envista's Q1 revenue reached $705.5 million, exceeding analyst expectations of $675.2 million by 14.4%, indicating robust growth driven by orthodontics, diagnostics, and consumables.
- Improved Profitability: Adjusted EPS was $0.36, beating the $0.31 estimate by 14.9%, while adjusted EBITDA stood at $98.9 million with a 14% margin, showcasing effective cost control measures.
- Cautious Market Reaction: Despite surpassing expectations, the market reacted negatively due to investor concerns over macroeconomic uncertainties and tariff impacts, with CEO Paul Keel acknowledging these as ongoing challenges.
- Future Outlook: Management reiterated full-year adjusted EPS guidance of $1.40, with expectations that China's Value-Based Procurement (VBP) will commence in Q2 or Q3, emphasizing the need to monitor market developments closely for revenue impacts.
See More
Envista Holdings Reports Strong Q1 2026 Earnings with 9.5% Core Growth
- Core Growth Performance: Envista achieved a 9.5% core growth in Q1 2026, with ortho consumables and diagnostics showing double-digit increases, despite weaker performance in China, indicating strong global demand and competitive positioning.
- Acquisition and Integration: The completion of the acquisition of Versah enhances Envista's implants platform, expected to boost growth, margins, and EPS, thereby solidifying its leadership in the medical device sector.
- Stock Buyback Program Expansion: The board authorized an additional $300 million for stock repurchases, reflecting management's confidence in future performance and a proactive strategy to enhance shareholder value through capital returns.
- Financial Outlook and Risks: Envista reaffirmed its 2026 guidance of 2% to 4% core growth, while acknowledging geopolitical and macroeconomic uncertainties, yet remains optimistic about future cash flow and profitability.
See More
Envista Releases 2026 Financial Outlook with Strong Q1 Results
- Q1 Performance Exceeds Expectations: Envista reported a Q1 non-GAAP EPS of $0.36, beating estimates by $0.05, indicating strong market performance that is likely to positively impact stock prices.
- Significant Revenue Growth: The company achieved Q1 revenue of $706 million, a 14.4% year-over-year increase, surpassing market expectations by $25.93 million, reflecting successful sales and market expansion efforts that bolster investor confidence.
- 2026 Financial Guidance: Envista maintains its 2026 core sales growth outlook at 2% to 4%, with adjusted EBITDA growth projected at 7% to 13%, demonstrating the company's confidence and stability in future growth prospects.
- Clear EPS Targets: The company anticipates adjusted diluted EPS for 2026 to be between $1.35 and $1.45, alongside nearly 100% free cash conversion, showcasing strong financial health and sustainable profitability.
See More
Envista to Report Q2 2026 Financial Results on August 5
- Earnings Release Schedule: Envista Holdings Corporation will report its Q2 2026 financial results on August 5, 2026, and will hold a conference call at 2:00 PM PT on the same day, lasting approximately one hour, reflecting the company's commitment to transparency and investor communication.
- Webcast and Replay: The conference call and accompanying slides will be webcast on the 'Investors' section of Envista's website, with a replay available for one year post-presentation, ensuring investors can access critical information at their convenience.
- Dial-in Participation: Investors can join the call by dialing 1-800-836-8184 within the U.S. or +1 646-357-8785 internationally a few minutes before 2:00 PM PT, referencing Conference ID #73468, demonstrating the company's focus on facilitating investor engagement.
- Company Background: Envista is a global leader in the dental industry, uniting over 30 trusted brands dedicated to improving patient lives through innovative technologies and services, showcasing its significant impact on modern dentistry.
See More
Envista to Report Q2 2026 Financial Results on August 5
- Earnings Release Schedule: Envista Holdings Corporation will report its Q2 2026 financial results on August 5, 2026, and will hold a conference call at 2:00 PM PT on the same day, lasting approximately one hour, reflecting the company's commitment to transparency and investor communication.
- Webcast and Replay: The conference call and accompanying slides will be webcast on the 'Investors' section of Envista's website, with a replay available for one year post-presentation, ensuring investors have access to critical information at their convenience.
- Dial-in Participation: Investors can participate by dialing 1-800-836-8184 within the U.S. or +1 646-357-8785 internationally a few minutes before the call, referencing Conference ID #73468, demonstrating the company's openness to global investor engagement.
- Company Background: Envista is a global leader in the dental industry, uniting over 30 trusted brands focused on improving patient lives through innovative technologies and services, showcasing its deep expertise and market influence in the dental sector.
See More
Henry Schein Appoints New Board Chairman
- New Board Chairman: Henry Schein announced that William K. 'Dan' Daniel will become the Independent Chairman of the Board effective May 21, 2026, succeeding Stanley M. Bergman, who served 44 years and is now Chairman Emeritus, recognizing his extraordinary contributions to the company.
- Rich Leadership Experience: Daniel joined the Henry Schein Board in May 2025 and brings decades of board and global executive leadership experience in healthcare and industrial sectors, having served 14 years as Executive Vice President at Danaher Corporation, overseeing multiple business segments including the dental portfolio.
- Strategic Continuity and Growth: Daniel expressed his commitment to building upon the foundation laid by Bergman, emphasizing the latter's strategic leadership and dedication to Henry Schein's mission, which has shaped the company into a leading industry provider, and he looks forward to supporting this legacy.
- Growth Outlook: CEO Fred Lowery expressed gratitude for Bergman's contributions and highlighted that Daniel's deep understanding of the business and distinguished track record will be instrumental in executing the company's long-term strategy, enhancing the quality and accessibility of healthcare services.
See More
Envista Reports Strong Q1 Sales Growth Amid Challenges
- Strong Sales Performance: Envista's Q1 revenue reached $705.5 million, exceeding analyst expectations of $675.2 million by 14.4%, indicating robust growth driven by orthodontics, diagnostics, and consumables.
- Improved Profitability: Adjusted EPS was $0.36, beating the $0.31 estimate by 14.9%, while adjusted EBITDA stood at $98.9 million with a 14% margin, showcasing effective cost control measures.
- Cautious Market Reaction: Despite surpassing expectations, the market reacted negatively due to investor concerns over macroeconomic uncertainties and tariff impacts, with CEO Paul Keel acknowledging these as ongoing challenges.
- Future Outlook: Management reiterated full-year adjusted EPS guidance of $1.40, with expectations that China's Value-Based Procurement (VBP) will commence in Q2 or Q3, emphasizing the need to monitor market developments closely for revenue impacts.
See More
Envista Holdings Reports Strong Q1 2026 Earnings with 9.5% Core Growth
- Core Growth Performance: Envista achieved a 9.5% core growth in Q1 2026, with ortho consumables and diagnostics showing double-digit increases, despite weaker performance in China, indicating strong global demand and competitive positioning.
- Acquisition and Integration: The completion of the acquisition of Versah enhances Envista's implants platform, expected to boost growth, margins, and EPS, thereby solidifying its leadership in the medical device sector.
- Stock Buyback Program Expansion: The board authorized an additional $300 million for stock repurchases, reflecting management's confidence in future performance and a proactive strategy to enhance shareholder value through capital returns.
- Financial Outlook and Risks: Envista reaffirmed its 2026 guidance of 2% to 4% core growth, while acknowledging geopolitical and macroeconomic uncertainties, yet remains optimistic about future cash flow and profitability.
See More
Envista Releases 2026 Financial Outlook with Strong Q1 Results
- Q1 Performance Exceeds Expectations: Envista reported a Q1 non-GAAP EPS of $0.36, beating estimates by $0.05, indicating strong market performance that is likely to positively impact stock prices.
- Significant Revenue Growth: The company achieved Q1 revenue of $706 million, a 14.4% year-over-year increase, surpassing market expectations by $25.93 million, reflecting successful sales and market expansion efforts that bolster investor confidence.
- 2026 Financial Guidance: Envista maintains its 2026 core sales growth outlook at 2% to 4%, with adjusted EBITDA growth projected at 7% to 13%, demonstrating the company's confidence and stability in future growth prospects.
- Clear EPS Targets: The company anticipates adjusted diluted EPS for 2026 to be between $1.35 and $1.45, alongside nearly 100% free cash conversion, showcasing strong financial health and sustainable profitability.
See More
